Patents Issued in July 4, 2017
-
Patent number: 9695403Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate.Type: GrantFiled: May 20, 2010Date of Patent: July 4, 2017Assignee: Syngenta Participations AGInventors: David P. Weiner, Arne I. Solbak, Jr., Ryan McCann
-
Patent number: 9695404Abstract: Described herein are genetically-modified microorganisms for producing long-chain dicarboxylic acids and methods of using the microorganisms. The microorganisms contain a first nucleic acid encoding an Umbellularia californica lauroyl ACP-thioesterase (BTE) operably linked to a promoter or a second nucleic acid encoding a Cocos nucifera lauroyl ACP-thioesterase (FatB3) operably linked to a promoter.Type: GrantFiled: July 17, 2015Date of Patent: July 4, 2017Assignee: Industrial Technology Research InstituteInventors: Hsin-Ju Hsieh, Liang-Jung Chien, Jia-Hung Wang, Yu-Ju Lin
-
Patent number: 9695405Abstract: The present invention relates to variants of a parent alpha-amylase, the variant having improved stability or activity at low calcium conditions or at low pH.Type: GrantFiled: June 17, 2016Date of Patent: July 4, 2017Assignee: NOVOZYMES A/SInventor: Carsten Andersen
-
Patent number: 9695406Abstract: The present invention relates to glucoamylase variants having increased thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: GrantFiled: March 6, 2014Date of Patent: July 4, 2017Assignee: NOVOZYMES A/SInventors: Esben P. Friis, Jesper Vind, Leonardo De Maria, Bjarne G. Hansen
-
Patent number: 9695407Abstract: The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having reduced binding to non-cellulosic materials. Also described are nucleic acids encoding the cellulase, compositions comprising said cellulase, methods of identifying cellulose variants and methods of using the compositions.Type: GrantFiled: March 19, 2015Date of Patent: July 4, 2017Assignee: DANISCO US INCInventors: Luis Cascao-Pereira, Thijs Kaper, Bradley R. Kelemen, Amy D. Liu
-
Patent number: 9695408Abstract: The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates.Type: GrantFiled: August 19, 2015Date of Patent: July 4, 2017Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Shekhar Kumar, Neeraj Maheshwari, Girish Sahni
-
Patent number: 9695409Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).Type: GrantFiled: August 24, 2016Date of Patent: July 4, 2017Assignee: Synthetic Biologics, Inc.Inventors: Michael Kaleko, Sheila Connelly
-
Patent number: 9695410Abstract: Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated GAD autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated GAD autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated GAD autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated GAD autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes.Type: GrantFiled: July 14, 2011Date of Patent: July 4, 2017Assignee: Technion Research & Development Foundation LimitedInventors: Yoram Reiter, Rony Dahan
-
Patent number: 9695411Abstract: The present invention is directed towards genetic modification of native gene encoding for sucrose isomerase and isomaltulose synthase to substantially increase the expression level of these enzymes and use of said enzymes in a process to produce rare disaccharides such as isomaltulose and trehalulose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.Type: GrantFiled: April 17, 2013Date of Patent: July 4, 2017Assignee: Petiva Private LimitedInventors: Samir Kumar Roy, Saravanakumar Iyappan, Saju Varghese, Aparna Devi Addala, Milky Agarwal, Kanumuru Rahul Raju, Banibrata Pandey
-
Patent number: 9695412Abstract: The present invention relates to single cell array micro-chips and fabrication, electrical measurement and electroporation method thereof. The single cell array microchip comprises a substrate (1), a plurality of positioning electrodes (2) formed in an array, a plurality of measuring electrode-pairs (3) formed in an array, and a micro sample pool (4). The invention integrates cell array positioning with electrical measurement and electroporation for living cells, which is characteristic of label-free and noninvasive methods to manipulate, position particles/cells as well as further measure their electrical parameters. Therefore, single-cell-array positioning and multi-mode in-situ real-time measurement can be realized for intensive analysis. Since the positioned cells are immobile, the precision of the electrical measurement of cells is effectively improved, so is the efficiency of electroporation with lower cell mortality rate.Type: GrantFiled: July 10, 2014Date of Patent: July 4, 2017Assignee: Tsinghua UniversityInventors: Rong Zhu, Xiaoliang Guo
-
Patent number: 9695413Abstract: An object of the present invention is to provide a technique for preparing RNA ready for an enzymatic reaction more easily than conventional techniques. The present invention provides a reagent for RNA extraction from a biological sample which contains an alkali metal salt and a surfactant.Type: GrantFiled: October 25, 2013Date of Patent: July 4, 2017Assignee: KANEKA CORPORATIONInventors: Sotaro Sano, Shigehiko Miyamoto, Jun Tomono, Hajime Hiratsuka
-
Patent number: 9695414Abstract: A device, method and system is provided for binding particles for the separation and/or isolation of biological materials. In particular, a container is provided including a suspension of binding particles for the isolation of biological material, inner walls forming an elongate groove at the bottom of said container, and a cover having openings and/or being penetrable for a linear arrangement of multiple pipets or pipet tips, said openings being located above and parallel to said elongate groove.Type: GrantFiled: February 9, 2015Date of Patent: July 4, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Geza Burghardt, Willem Mulder, Rolf Schneebeli
-
Patent number: 9695415Abstract: Methods of making and using bacterial display polypeptide libraries using circularly permuted OmpX (CPX) variants are disclosed. The invention further relates to methods for enhancing the display of proteins and peptides at the surface of bacteria by optimizing linkers and incorporating mutations at positions 165 and 166 of CPX.Type: GrantFiled: May 20, 2015Date of Patent: July 4, 2017Assignee: The Regents of the University of CaliforniaInventors: Patrick Sean Daugherty, Jeffrey Rice
-
Patent number: 9695416Abstract: The present disclosure relates to normalization of biological samples, particularly samples comprising nucleic acids to be sequenced. The normalization protocols described herein may be utilized across multiple samples to cap total stoichiometric input and minimize variations in transcript abundance on a per-sample basis in a multiplexed fashion to dramatically increase the accuracy, capacity and efficiency of nucleic acid sequencing.Type: GrantFiled: July 18, 2013Date of Patent: July 4, 2017Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Thomas Battersby, Adrian Nielsen Fehr, Minxue Zheng
-
Patent number: 9695417Abstract: Systems and methods for synthesizing long-chain nucleic acids molecules are disclosed. The systems and methods described in this application use a Ligation-Purification-Amplification (“LPA”) technique. The LPA technique requires first producing nucleotide sequences with the length of at least 500 bp-1 kbp by assembling smaller oligonucleotide fragments (30 bp-200 bp). The assembled nucleotide sequences are then purified and amplified. This technology can be used to achieve parallel amplification of three or more nucleotide sequences at the same time. In embodiments of the invention, a solid-phase ligation-purification method is adopted, in which nucleic acid molecules are fixed on the surface of beads or other solid particles in order to rapidly purify products obtained from the ligation reaction.Type: GrantFiled: June 13, 2012Date of Patent: July 4, 2017Inventors: Qianjun Ma, Shaolu Li
-
Patent number: 9695418Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the present invention provides compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides comprise a region having a gapmer sugar motif. In certain embodiments, oligonucleotides comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif.Type: GrantFiled: October 11, 2013Date of Patent: July 4, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Susan M. Freier, Brett P. Monia, Eric E. Swayze
-
Patent number: 9695419Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: April 20, 2015Date of Patent: July 4, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Patent number: 9695420Abstract: The present invention provides a method of identifying host cell molecules which may be modulated to inhibit viral replication and method of testing antiviral compounds. In addition, the invention provides compositions, methods and medicaments for treating viral infections and/or diseases or conditions caused or contributed to by viruses.Type: GrantFiled: August 25, 2014Date of Patent: July 4, 2017Assignee: The University Court of the University of EdinburghInventor: Amy Buck
-
Patent number: 9695421Abstract: The present invention relates to a dengue virus-specific siRNA, a double-stranded oligo RNA structure comprising the siRNA, and a composition for inhibiting dengue virus replication, which comprises the same, in which the double-stranded oligo RNA structure comprises a hydrophilic compound and hydrophobic compound conjugated to both ends of the double-stranded RNA (siRNA) by a single covalent bond or a linker-mediated covalent bond so that they will be efficiently delivered into cells, and can be converted into nanoparticles by hydrophobic interactions between the double-stranded oligo RNA structures in an aqueous solution. The siRNA included in the double-stranded oligo RNA structure acts specifically on all dengue virus serotypes. The present invention also relates to a method for preparing the double-stranded oligo RNA structure, and a pharmaceutical composition for preventing or treating dengue virus infection, which comprises the double-stranded oligo RNA structure.Type: GrantFiled: July 4, 2014Date of Patent: July 4, 2017Assignee: BIONEER CORPORATIONInventors: Joo Sung Yang, Woo Seok Kim, Soon Ja Choi, Han Oh Park
-
Patent number: 9695422Abstract: Compositions and methods to attenuate the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: September 3, 2015Date of Patent: July 4, 2017Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9695423Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: December 22, 2015Date of Patent: July 4, 2017Assignee: SILENCE THERAPEUTICS GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9695424Abstract: Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.Type: GrantFiled: September 8, 2014Date of Patent: July 4, 2017Assignee: SomaLogic, Inc.Inventors: Nebojsa Janjic, Daniel W. Drolet, Amy D. Gelinas, Chi Zhang, Michael Vrkljan
-
Patent number: 9695425Abstract: In one embodiment, a B cell specific aptamer-siRNA chimera is provided. The B cell specific aptamer-siRNA chimera may include an RNA aptamer that binds BAFF-R and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. In another embodiment, a B cell specific RNA aptamer is provided. The RNA aptamer may be a molecule that binds to BAFF-R that has the sequence SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In some embodiments, the RNA aptamer is conjugated, via a nucleotide linker, to an siRNA molecule that suppresses expression of one or more target oncogenes in one or more B cells. In one aspect, the one or more target oncogenes are selected from Bcl6, Bcl2, STAT3, Cyclin D1, Cyclin E2 and c-myc. In another embodiment, methods for treating a B cell malignancy in a cancer patient are provided. Such methods may include administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific RNA aptamer that binds BAFF-R.Type: GrantFiled: May 27, 2016Date of Patent: July 4, 2017Assignee: CITY OF HOPEInventors: John Rossi, Katrin Tiemann, Jiehua Zhou, Britta Vallazza
-
Patent number: 9695426Abstract: Provided herein are metabolically-modified microorganisms useful for producing biofuels. More specifically, provided herein are methods of producing high alcohols including isobutanol, 1-butanol, 1-propanol, 2-methyl-1-butanol, 3-methyl-1-butanol and 2-phenylethanol from a suitable substrate.Type: GrantFiled: August 12, 2009Date of Patent: July 4, 2017Assignee: The Regents of the University of CaliforniaInventors: James C. Liao, Shota Atsumi, Anthony F. Cann
-
Patent number: 9695427Abstract: Testosteronan, a heparosan analog having the structure [-4-D-GlcUA-?1,4-D-GlcNAc-?1-]n, is produced by testosteronan synthase, a single protein that is a dual-action catalyst that utilizes UDP-GlcUA and UDP-GlcNAc to synthesize a polysaccharide having the structure [-4-D-GlcUA-?1,4-D-GlcNAc-?1-]n.Type: GrantFiled: January 31, 2012Date of Patent: July 4, 2017Assignee: The Board of Regents of the University of OklahomaInventors: Paul L. DeAngelis, Nigel J. Otto
-
Patent number: 9695428Abstract: This invention relates to a biological indicator derived from a composition comprising: a host organism comprising a spore forming bacteria; a reporter gene for producing an indicator enzyme; a regulatory gene; and a vehicle for inserting the reporter gene and the regulatory gene in the host organism; the host organism bearing a transposable genetic element in its genome for inserting an insertion sequence in the regulatory gene; the insertion sequence comprising a transposase, a pair of terminal inverted repeat sequences, and at least one open reading frame for expressing the transposase. The vehicle may be taken up by the host organism. The insertion sequence may be inserted in the regulatory gene. The host organism may undergo sporulation to form the biological indicator. A process and an apparatus for using the biological indicator are disclosed.Type: GrantFiled: July 7, 2016Date of Patent: July 4, 2017Assignee: American Sterilizer CompanyInventors: Phillip P. Franciskovich, Tricia A. Cregger, William A. Yirava, Peter A. Burke
-
Patent number: 9695429Abstract: The present invention relates to methods for producing a biological substance, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the biological substance, wherein the fungal host cell comprises a first nucleic acid sequence encoding the biological substance operably linked to a second nucleic acid sequence comprising a promoter variant selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12; and a subsequence thereof; and hybrid and tandem promoters thereof; and (b) isolating the biological substance from the cultivation medium. The present invention also relates to the isolated promoter variants and to constructs, vectors, and fungal host cells comprising the promoter variants operably linked to nucleic acid sequences encoding biological substances.Type: GrantFiled: September 10, 2015Date of Patent: July 4, 2017Assignee: NOVOZYMES, INC.Inventors: Debbie Yaver, Peter Nham
-
Patent number: 9695430Abstract: The present invention relates to a method for genetically modifying a filamentous fungus host for improved protein production. The method comprises that a filamentous fungus host is genetically modified to overexpress or to be deficient of specific genes. The invention relates also to the modified hosts. Furthermore, the invention relates to a method for improved production or for producing an improved composition of proteins, such as cellulases, hemicellulases, other proteins involved in the degradation of lignocellulosic material, or other proteins, in a filamentous fungus host.Type: GrantFiled: December 21, 2015Date of Patent: July 4, 2017Assignee: Teknologian Tutkimuskeskus VTT OYInventors: Tiina Pakula, Markku Saloheimo, Mari Hakkinen, Ann Westerholm-Parvinen, Merja Penttila, Marika Vitikainen
-
Patent number: 9695431Abstract: Described herein is a process of genetic transformation in W. somnifera by Agrobacterium tumefaciens mediated transformation to overexpress squalene synthase gene (WsSQS) encoding WsSQS enzyme that catalyzes the synthesis of squalene from farnesyl pyrophosphate. Increased withanolide level including withaferin-A, withanolide A and B and withanone is attained in transformed plant tissues.Type: GrantFiled: September 25, 2014Date of Patent: July 4, 2017Assignee: Council of Scientific and Industrial ResearchInventors: Bashir Mohammad Khan, Neha Gupta, Parth Sanjaykumar Patel, Poonam Sharma, Shuchishweta Vinay Kendurkar
-
Patent number: 9695432Abstract: A method for deleting a region of DNA in a plant. In some embodiments, the method comprises transforming a plant with a nucleic acid molecule, wherein the nucleic acid molecule encodes one or more zinc finger nuclease(s) (ZFNs) operably linked to one or more tissue-specific promoter(s), e.g., a pollen-specific promoter. Methods include excising native genes in a plant. Accordingly, in some embodiments, ZFNs are engineered that recognize sequences that flank native plant genes. In further embodiments, ZFNs are expressed under the control of developmental stage-specific promoters, such that, for example, nucleic acid sequences are specifically excised in plants during relatively late stages of development. Nucleic acid molecules useful for carrying out disclosed methods and plants produced by the methods are included.Type: GrantFiled: January 21, 2011Date of Patent: July 4, 2017Assignee: Dow AgroSciences LLCInventors: Sean M. Russell, Joseph F. Petolino
-
Patent number: 9695433Abstract: The present invention relates to isolated polypeptides having beta-xylosidase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: November 22, 2012Date of Patent: July 4, 2017Assignee: Novozymes Inc.Inventors: Yu Zhang, Ye Liu, Junxin Duan, Lan Tang, Brett McBrayer
-
Patent number: 9695434Abstract: Brassica plants producing oils with a low alpha-linolenic acid content and methods for producing such plants are described.Type: GrantFiled: November 26, 2012Date of Patent: July 4, 2017Assignee: CARGILL, INCORPORATEDInventors: Daren Coonrod, Kevin Brandt, Honggang Zheng, Zhizheng Chen, Richard Fletcher
-
Patent number: 9695435Abstract: A technique by which the production of plant biomass can be significantly increased is provided. A protein phosphatase 2C gene having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 from the N-terminal side in such order is over-expressed.Type: GrantFiled: January 30, 2015Date of Patent: July 4, 2017Assignees: TOYOTA JIDOSHA KABUSHIKI KAISHA, OKAYAMA PREFECTUREInventors: Satoshi Kondo, Chikara Ohto, Norihiro Mitsukawa, Nobuhiko Muramoto, Kenichi Ogawa, Hiroki Sugimoto, Tomoko Tanaka, Madoka Yonekura
-
Patent number: 9695436Abstract: Methods are provided for enhancing yield and nitrogen use efficiency in plants, and to methods of increasing biomass and seed yield in plants grown under nitrogen limiting conditions using variants of enzymes involved in nitrogen assimilation or metabolism from non-plant organisms.Type: GrantFiled: March 4, 2014Date of Patent: July 4, 2017Assignee: BAYER CROPSCIENCE LPInventors: Chandra McAllister, Perrin Beatty, Jayne D'Entremont, Allen Good
-
Patent number: 9695437Abstract: The present invention relates to an isolated COP1 nucleic acid sequence from a maize plant and the isolated COP1 nucleic acid sequence is named as ZmCOP1. The present invention also relates to a method of using the ZmCOP1 nucleic acid sequence to control the shade avoidance response of a crop plant for high density farming and yield enhancement.Type: GrantFiled: June 25, 2014Date of Patent: July 4, 2017Assignee: Monsanto Technology LLCInventors: Nordine Cheikh, Molian Deng, Philip W. Miller, Nanfei Xu
-
Patent number: 9695438Abstract: The present invention is directed to wheat plants having increased resistance to an imidazolinone herbicide. More particularly, the present invention includes wheat plants containing one or more IMI nucleic acids such as a Teal IMI cultivar. The nucleic acids are preferably located on or derived from different genomes. The present invention also includes seeds produced by these wheat plants and methods of controlling weeds in the vicinity of these wheat plants.Type: GrantFiled: October 4, 2016Date of Patent: July 4, 2017Assignee: University of SaskatchewanInventors: Curtis J. Pozniak, Pierre Hucl
-
Patent number: 9695439Abstract: The present invention relates to control of pest infestation by inhibiting one or more biological functions. The invention provides methods and compositions for such control, By feeding one or more recombinant double stranded RNA molecules provided by the invention to the pest, a reduction in pest infestation is obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.Type: GrantFiled: April 2, 2013Date of Patent: July 4, 2017Assignee: Monsanto Technology LLCInventors: James A. Baum, Claire A. CaJacob, Pascale Feldmann, Gregory R. Heck, Irene Maria Antonia Nooren, Geert Plaetinck, Ty T. Vaughn, Wendy Maddelein
-
Patent number: 9695440Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:4-19, or the nucleotide sequence set forth in SEQ ID NO: 1-3, as well as variants and fragments thereof.Type: GrantFiled: March 29, 2012Date of Patent: July 4, 2017Assignee: Athenix Corp.Inventor: Kimberly Sampson
-
Patent number: 9695441Abstract: Soybean event 9582.814.19.1 comprising genes encoding Cry1F, Cry1Ac (synpro), and PAT, affording insect resistance and herbicide tolerance to soybean crops containing the event, and enabling methods for crop protection and protection of stored products.Type: GrantFiled: March 24, 2014Date of Patent: July 4, 2017Assignee: Dow AgroSciences LLCInventors: Nathan Bard, Gregory A. Bradfisch, Yunxing C. Cui, James E. Dripps, Thomas Hoffman, Dayakar Pareddy, Dawn M. Parkhurst, Sandra G. Toledo, Barry Wiggins, Ning Zhou
-
Patent number: 9695442Abstract: Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites.Type: GrantFiled: March 4, 2013Date of Patent: July 4, 2017Assignee: Sangamo Therapeutics, Inc.Inventors: Dmitry Guschin, Fyodor Urnov
-
Patent number: 9695443Abstract: The present invention relates to a viral vector for silencing a gene specifically in astrocytes comprising: —an astrocyte-specific viral envelope protein, —a first nucleic acid sequence encoding a transcription activator and at least one target sequence of a neuron-specific miR under the control of an astrocyte-specific promoter, and—a second nucleic acid sequence encoding a RNA for silencing the gene under the control of a promoter inducible by the transcription activator.Type: GrantFiled: May 24, 2013Date of Patent: July 4, 2017Assignee: Commissariat a l'Energie Atomique et aux Energies AlternativesInventor: Nicole Deglon
-
Patent number: 9695444Abstract: Disclosed are: a virus vector in which a gene encoding an antigenic polypeptide is integrated in human parainfluenza virus type 2 gene, wherein the antigenic polypeptide is expressed in the form of a fusion protein with a viral structural protein; and a method for producing the same. The virus vector of the present invention contains a quantitatively large amount of the antigenic peptide on the virus particle and can efficiently deliver the antigenic polypeptide to a target cell.Type: GrantFiled: December 25, 2013Date of Patent: July 4, 2017Assignees: BIOCOMO INC., MIE UNIVERSITYInventors: Masayuki Fukumura, Junpei Ohtsuka, Tetsuya Nosaka, Masato Tsurudome, Mitsuo Kawano, Ken-ichiro Hara
-
Patent number: 9695445Abstract: An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.Type: GrantFiled: July 29, 2015Date of Patent: July 4, 2017Assignee: ID Pharma Co., Ltd.Inventors: Noemi Fusaki, Hiroshi Ban, Mamoru Hasegawa, Yoshikazu Yonemitsu
-
Patent number: 9695446Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.Type: GrantFiled: February 25, 2014Date of Patent: July 4, 2017Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Philippe Mangeot, Vincent Lotteau
-
Patent number: 9695447Abstract: An object of the present invention is to provide a series of techniques for producing isoprene from methanol or the like. Provided is a recombinant cell prepared by introducing a gene encoding isoprene synthase, into a host cell which is a methylotroph, wherein the gene is expressed in the host cell, and the recombinant cell is capable of producing isoprene from at least one C1 compound selected from the group consisting of methane, methanol, methylamine, formic acid, formaldehyde, and formamide. Preferably, it has at least one C1 carbon assimilating pathway selected from the group consisting of a serine pathway, a ribulose monophosphate pathway, and a xylulose monophosphate pathway as a fixing pathway of formaldehyde. Also provided is a method for producing isoprene using the recombinant cell.Type: GrantFiled: December 26, 2013Date of Patent: July 4, 2017Assignee: SEKISUI CHEMICAL CO., LTD.Inventors: Masahiro Furutani, Akihiro Uenishi, Koichiro Iwasa
-
Patent number: 9695448Abstract: The present invention provides a biosafety-guarded photobiological butanol production technology based on designer transgenic plants, designer algae, designer blue-green algae (cyanobacteria and oxychlorobacteria), or designer plant cells. The designer photosynthetic organisms are created such that the endogenous photobiological regulation mechanism is tamed, and the reducing power (NADPH) and energy (ATP) acquired from the photosynthetic process are used for synthesis of butanol (CH3CH2CH2CH2OH) directly from carbon dioxide (CO2) and water (H2O). The butanol production methods of the present invention completely eliminate the problem of recalcitrant lignocellulosics by bypassing the bottleneck problem of the biomass technology.Type: GrantFiled: April 4, 2014Date of Patent: July 4, 2017Inventor: James Weifu Lee
-
Patent number: 9695449Abstract: The present invention generally relates to oil compositions and methods of producing such oil compositions. More particularly, the present invention relates to an oil composition recovered from a fermentation product as well as methods of recovering such oil compositions for use in various processes such as bio-diesel production as well as in various edible applications.Type: GrantFiled: December 23, 2013Date of Patent: July 4, 2017Assignee: POET, LLCInventor: Jason Bootsma
-
Patent number: 9695450Abstract: The amino acid and nucleic acid sequences of a ?5-desaturase enzyme and a ?8-desaturase enzyme are disclosed. The nucleic acid sequences can be used to design recombinant DNA constructs and vectors. These vectors can then be used to transform various organisms, including for example, plants and yeast. The transformed organisms will then produce polyunsaturated fatty acids. The amino acid sequences are useful for generating enzyme-specific antibodies that are useful for identifying the desaturases.Type: GrantFiled: June 18, 2014Date of Patent: July 4, 2017Assignee: Washington State UniversityInventors: John A. Browse, James G. Wallis, Jennifer L. Watts
-
Patent number: 9695451Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.Type: GrantFiled: October 6, 2016Date of Patent: July 4, 2017Assignee: Codexis, Inc.Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
-
Patent number: 9695452Abstract: This invention relates to DNA encoding a novel enzyme having activity of synthesizing D-serine from formaldehyde and glycine, recombinant DNA constructed by integrating such DNA into a vector, a transformant transformed with the recombinant DNA, and a method for producing D-serine from formaldehyde and glycine with the use of the enzyme.Type: GrantFiled: October 30, 2015Date of Patent: July 4, 2017Assignee: MITSUI CHEMICALS, INC.Inventors: Tadashi Araki, Tomonori Hidesaki, Seiichi Watanabe, Keita Nishida, Kiyoteru Nagahara, Mitsuo Koito